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Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is an established pathogen that causes hospital- and
community-acquired infections worldwide. The prevalence rate of MRSA infections were reported to be the highest in
Asia. As there is limited epidemiological study being done in Malaysia, this study aimed to determine the prevalence of
MRSA infection and the molecular characteristics of MRSA bacteraemia.
Methods: Two hundred and nine MRSA strains from year 2011 to 2012 were collected from a tertiary teaching hospital
in Malaysia. The strains were characterized by antimicrobial susceptibility testing, staphylococcal cassette chromosome
mec (SCCmec) typing, detection of Panton-Valentine leukocidin (PVL) gene, multilocus sequence typing (MLST) and
pulsed-field gel electrophoresis (PFGE). Patient’s demographic and clinical data were collected and correlated with
molecular data by statistical analysis.
Results: Male gender and patient >50 years of age (p < 0.0001) were significantly associated with the increased risk of
MRSA acquisition. Fifty-nine percent of MRSA strains were HA-MRSA that carried SCCmec type II, III, IV and V while 31%
were CA-MRSA strains with SCCmec III, IV and V. The prevalence of PVL gene among 2011 MRSA strains was 5.3% and
no PVL gene was detected in 2012 MRSA strains. All of the strains were sensitive to vancomycin. However, vancomycin
MIC creep phenomenon was demonstrated by the increased number of MRSA strains with MIC ≥1.5 μg/mL (p = 0.008)
between 2011 and 2012. Skin disease (p = 0.034) and SCCmec type III (p = 0.0001) were found to be significantly
associated with high vancomycin MIC. Forty-four percent of MRSA strains from blood, were further subtyped by
MLST and PFGE. Most of the bacteraemia cases were primary bacteraemia and the common comorbidities were
diabetes, hypertension and chronic kidney disease. The predominant pulsotype was pulsotype C exhibited by
SCCmec III-ST239. This is a first study in Malaysia that reported the occurrence of MRSA clones such as SCCmec
V-ST5, untypeable-ST508, SCCmec IV-ST1 and SCCmec IV-ST1137.
Conclusions: SCCmec type III remained predominant among the MRSA strains in this hospital. The occurrence of
SCCmec IV and V among hospital strains and the presence of SCCmec III in CA-MRSA strains are increasing. MRSA
strains causing bacteraemia over the two-year study period were found to be genetically diverse.
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Background
Methicillin-resistant Staphylococcus aureus (MRSA) is
widely recognized as one of the pathogens causing
hospital- and community- acquired infections. MRSA is
highly prevalent in hospitals worldwide in which high
rates (>50%) were reported in Asia, Malta, North and
South America [1]. The prevalence of MRSA in Malaysia
ranged from 17% in 1986 [2] to 44.1% in 2007 [3].
MRSA is evolved from methicillin-susceptible S. aureus
through the acquisition of Staphylococcal cassette
chromosome mec (SCCmec) which carries mecA gene.
mecA gene encodes the penicillin-binding protein (PBP2a)
which confers resistance to all β-lactam antibiotics [4].
Hospital-acquired (HA)-MRSA strains cause nosoco-
mial infections and are associated with SCCmec type I,
II or III. In the 1990s, the epidemiology of MRSA infec-
tions has changed due to the emergence of community-
acquired (CA)-MRSA strains. CA-MRSA strains cause skin
and soft tissue infections (SSTIs), sepsis, osteomyelitis, nec-
rotizing pneumonia and fasciitis and pyomyositis in
children, soldiers, professional football players or incarcer-
ated populations. They often carry Panton-Valentine leuko-
cidin (PVL) genes and SCCmec IV or V [4, 5]. To date,
eleven different SCCmec types (I-XI) have been defined [6].
However, only SCCmec type I-V are globally distributed
while others are uncommon and may exist as local strains
in their original country [7].
There are various discriminative methods to type
MRSA and to determine its molecular epidemiology.
These methods include SCCmec typing, pulsed-field gel
electrophoresis (PFGE) and multilocus sequence typing
(MLST) [1]. In brief, SCCmec polymerase chain reaction
(PCR) typing allows the presumptive assignment of all
SCCmec types to MRSA strains which differentiates
between HA-MRSA and CA-MRSA [8]. PFGE is based
on DNA fingerprints generated by rare restriction endo-
nuclease digestion and is useful for investigating nosoco-
mial outbreaks as well as to identify MRSA strains that
may cause major outbreaks. MLST is a highly discrimin-
atory method used for the investigation of the molecular
evolution of MRSA. It is based on the sequences of
450-bp internal fragments of 7 housekeeping genes
amplified by PCR. The sequences of the genes are com-
pared to those in MLST website (http://www.mlst.net)
which results in an allelic profile or sequence type (ST).
By using the eBURST software (http://eburst.mlst.net/
v3/mlst_datasets/), clonal complex (CC) can be defined
based upon the STs, in which the evolutionary events
can be analyzed [8, 9].
The most prevalent CCs reported worldwide are CC8
(ST239), CC5 (ST5) and CC22 (ST22) [1]. Numerous
genetic linkages of CA-MRSA have been reported to be
globally distributed. These include ST30-IV, ST8-IV,
ST1-IV, ST59-V and ST80-IV [10]. Previous studies done
by Lim et al. [11, 12] on 2003 and 2008 MRSA isolates
in this same tertiary teaching hospital and on 2008 to
2010 MRSA isolates in a tertiary hospital in Terengganu
had reported SCCmec type III and MLST type ST239 to
be the predominant clone. Similar findings were also
reported by Ghaznavi-Rad et al. [13], where 90% of
MRSA infections in another tertiary hospital belonged to
MLST type ST239. CA-MRSA strains in Malaysian
hospitals were reported to belong to SCCmec type
IV-MLST type ST30 based on study done by Ahmad
et al. [3] on 2006 and 2008 MRSA strains from nine
Malaysian hospitals.
Nosocomial bacteraemia has been reported to be
common in hospitals worldwide leading to high mortality
rate [14] and in Malaysia, 21% cases of bacteraemia were
reported to be caused by MRSA [15]. International MRSA
clones such as ST22-SCCmec IV, ST239-SCCmec III,
ST5-SCCmec II [16] ST30-SCCmec IV and ST1-SCCmec
IV [17] were reported to be spreading around the
world, disseminating between and within the coun-
tries. HA-MRSA strains had also been found circulat-
ing in the community and CA-MRSA strains were
reported to cause the outbreak of HA infections [18].
These epidemiological changes in MRSA have posed
great threat to the public health. However, limited
epidemiological studies have been done in Malaysian
hospitals to monitor the trends in MRSA infections.
The importance of continuous surveillance programs
and molecular epidemiological studies; apart from
proper infection control practices and antibiotic
stewardship in designing effective and rational patho-
gen control strategies in hospitals were highlighted in
an example of decreased rate of MRSA infections in
Japan and Taiwan from 71.6% in 2001 to 41% in 2011
and 68.8% in 2000 to 55.9% in 2010, respectively [19]
Therefore, the objectives of the study were to
characterize the MRSA strains from year to 2011 to
2012 and to determine the characteristics of MRSA
bacteraemia in the tertiary teaching hospital by
molecular typing such as SCCmec and PVL PCR
typing, MLST and PFGE.
Methods
Setting
UMMC is a 980-bed referral and teaching hospital in
Malaysia consisting of intensive care units, paediatric,
orthopaedic, surgical, medical, obstetrics and gynaecology
and psychiatry wards and clinics.
Bacterial strains
All adult patients (>16 years old) who fulfilled the
criteria for MRSA infection were included in this study.
This study was approved by Medical Ethic Committee of
University Malaya Medical Centre (UMMC) on 7th June
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2014 (MEC ID: 20145-168). A total of 209 non-
duplicate MRSA clinical strains were collected retro-
spectively from University Malaya Medical Centre
(UMMC). The strains were previously isolated from
sterile sites such as cerebrospinal fluid (CSF), synovial
fluid, tissue, bone, pus and blood in January 2011 to
December 2012. Only strains from pus that was
clinically significant and obtained in an aseptic man-
ner either in operation theatre (OT) or procedure
room was included in this study. The identities of the
strains were confirmed with PCR targeting femA gene
and identified as MRSA using standard microbio-
logical methods such as tube coagulase test, DNase
and cefoxitin disk (FOX) screen test.
These strains were characterized using antimicrobial
susceptibility testing, SCCmec typing and PCR targeting
PVL gene. Ninety-one selected strains isolated from
blood were further subtyped by PFGE and MLST.
Antimicrobial susceptibility testing
Vancomycin minimum inhibitory concentration (MIC)
results based on E-test were collected from the hospi-
tal’s microbiology diagnostic laboratory. The interpret-
ation was done according to Clinical and Laboratory
Standards Institute (CLSI) guidelines.
SCCmec typing and PCR-based assays for PVL gene
Crude genomic DNA was extracted by using simple
boiling method and the supernatant was used as DNA
template for PCR analysis. The cycling condition and
primers as described by Milheirico et al. [20] were used
to detect SCCmec types. For further subgrouping
SCCmec type IV strains, the cycling condition as
described by Milheirico et al. [21] and specific primers
4a1, 4a2, 4b1, 4b2, 4c1, 4c2, 4d1 and 4d2 as described by
Zhang et al. [22] were used. The following strains: 85/
2082 (SCCmec type III), JCSC2172 (SCCmec type IVb),
JCSC4744 (SCCmec type IVa), JCSC4469 (SCCmec type
IVd), MR108 (SCCmec type IVc), N315 (SCCmec type II),
NCTC10442 (SCCmec type I) and WIS (SCCmec type V)
were kindly provided by K.L. Thong, University of Malaya
and used as positive control strains to optimize the multi-
plex PCR assay. The detection of PVL gene was
performed as described by Holmes et al. [23] with slight
modification. Briefly, the amplification was performed in a
final volume of 25 μl containing 2 μl of DNA template, 1X
PCR buffer, 1.5 mM MgCI2, 0.2 mM dNTPs, 0.5 μl of Taq
polymerase (Promega Corporation, USA) and 0.2 μl of
primers luk-PV-1 and luk-PV-2 (Integrated DNA
Technologies, USA). The cycling conditions were as
described and the PCR products were analyzed by electro-
phoresis in a 1% agarose gel.
MLST and PFGE
MLST was performed as previously described by Enright
et al. [24]. The sequence types (STs) were assigned by
comparing the sequences of each locus to those in the S.
aureus MLST database (http://saureus.mlst.net) and
clonal complexes were defined by eBURST program.
PFGE was performed according to the Centers for
Disease Control and Prevention (CDC) PulseNet proto-
col [25] with slight modification. In brief, a single colony
of bacteria was streaked onto TSA (BD Difco™) and
incubated at 37 °C overnight. An aliquot of 100 μl of
bacterial cell suspension (containing bacterial culture in
cell suspension buffer) was transferred to a microcentri-
fuge tube and added with lysostaphin (1 mg/mL) and
lysozyme (10 mg/mL) (Sigma-Aldrich, USA). Following
incubation at 37 °C, proteinase K (20 mg/mL) (Promega
Corporation, USA) and 1% seakem gold agarose (Lonza,
USA) were added into the suspension, mixed and
allowed to solidify in a plug mold. The plug was trans-
ferred into cell lysis buffer (CLB), incubated at 54 °C for
3 h and washed with sterile distilled water and TE buf-
fer. A slice of plug was cut and digested with SmaI (Pro-
mega Corporation, USA) followed by separation on
CHEF MAPPER in 0.5X TBE at 14 °C for 22 h with
pulse time of 5 – 60 s. The Salmonella ser. Bran-
derup isolate H9812 was used as the reference strain.
The gel was stained in Gel Red dye (Biotium, USA)
and visualized under BioRad GelDoc XR. BioNu-
merics 6.5 Software package was used for cluster ana-
lyses of PFGE profiles based on the unweighted pair
group method with arithmetic averages (UPGMA)
with a tolerance of 1.5% and optimization of 1%. The
PFGE profile was assigned an arbitrary designation
and the Dice coefficient of similarity, F defined the
differences [11].
Clinical data collection
Patient’s demographic and clinical data such as age,
gender, diagnosis, comorbidities, site of infection, health-
care- associated risk factors were collected from the hospi-
tal’s medical record unit. Based on the CDC definitions,
HA-MRSA is defined as positive culture obtained more
than 48 h after hospital admission, or history of previous
hospitalization or medical procedures. CA-MRSA refers
to cases with positive culture obtained less than 48 h of
admission without healthcare-associated risk factors
[18, 26]. In this study, MRSA infection were defined
as HA- or CA- MRSA based upon the data collected
from patient’s clinical notes and from the Infection
Control Department’s database on multidrug resistant
organisms (MDROs). By using these two sources, the
risk factors for HA- and CA- MRSA infections were
identified with reasonable accuracy.
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Table 1 Comparisons between the patients’ demographics, phenotypic and genotypic characteristics of HA-MRSA and CA-MRSA in
2011 and 2012
2011 2012 P
value
Total P value
N = 95 (%) N = 114 (%) N = 209 (%)
Age
≤ 50 years old 39 (41.1) 27 (23.7) 0.011 66 (31.6) < 0.0001
> 50 years old 52 (54.7) 86 (75.4) 0.002 138 (66)
Not Known 4 (4.2) 1 (0.9) 5 (2.4)
Gender
Female 30 (31.6) 44 (38.6) 0.312 74 (35.4) < 0.0001
Male 62 (65.3) 70 (61.4) 0.666 132 (63.2)
Not Known 3 (3.2) 0 (0) 3 (1.4)
Source
Blood 40 (42.1) 51 (44.7) 0.780 91 (43.5)
Tissue 37 (38.9) 42 (36.8) 0.776 79 (37.8)
CSF 3 (3.2) 0 (0) 0.092 3 (1.4)
Pus, slough & Abscess 8 (8.4) 11 (9.6) 0.813 19 (9.1)
Pericardial fluid 1 (1.1) 0 (0) 0.455 1 (0.5)
Bullae fluid 0 (0) 1 (0.9) 1.000 1 (0.5)
Synovial fluid 2 (2.1) 2 (1.8) 1.000 4 (1.9)
Bone 4 (4.2) 7 (6.1) 0.758 11 (5.3)
SCCmec types
SCCmec I 0 (0) 0 (0) 0 (0)
SCCmec II 2 (2.1) 0 (0) 0.205 2 (0.9)
SCCmec III 61 (64.2) 78 (68.4) 0.558 139 (66.5)
SCCmec IV
SCCmec IVa 5 (5.3) 4 (3.5) 0.735 9 (4.3)
SCCmec IVb 5 (5.3) 0 (0) 0.018 5 (2.4)
SCCmec IVc 0 (0) 0 (0) 0 (0)
SCCmec IVd 0 (0) 0 (0) 0 (0)
Novel subtypes 15 (15.8) 30 (26.3) 0.090 45 (21.5)
SCCmec V 6 (6.3) 1 (0.9) 0.048 7 (3.3)
Untypeable 1 (1.1) 1 (0.9) 1.000 2 (0.9)
Type of MRSA
HA-MRSA 44 (46.3) 79 (69.3) 0.001 123 (58.9)
SCCmec II 2 (4.5) 0 (0) 0.126 2 (1.6)
SCCmec III 35 (79.5) 56 (70.9) 0.392 91 (73.9)
SCCmec IV
SCCmec IVa 1 (2.3) 3 (3.8) 1.000 4 (3.3)
SCCmec IVb 3 (6.8) 0 (0) 0.044 3 (2.4)
Novel subtypes 3 (6.8) 19 (24.1) 0.025 22 (17.9)
SCCmec V 0 (0) 1 (1.3) 1.000 1 (0.8)
CA-MRSA 41 (43.2) 24 (21.1) 0.001 65 (31.1)
SCCmec III 23 (56.1) 13 (54.2) 1.000 36 (55.4)
SCCmec IV
Sit et al. BMC Infectious Diseases  (2017) 17:274 Page 4 of 14
Statistical analysis
Categorical data were compared using Fisher exact test.
All reported p values are two-tailed and analyses were
performed using GraphPad software (https://www.graph
pad.com/quickcalcs/catMenu/). Variables with p < 0.05
were considered to be statistically significant.
Results
Distribution of MRSA strains
In this study, 209 MRSA strains from year 2011 to 2012
were collected from various clinical specimens including
tissues (n = 79; 37.8%), blood (n = 91; 43.5%), pus,
slough and abscess (n = 19; 9.1%), cerebrospinal fluid
(n = 3; 1.4%), bone (n = 11; 5.3%), pericardial fluid
(n = 1; 0.5%), bullae fluid (n = 1; 0.5%) and synovial fluid
(n = 4; 1.9%). The median age was 58 years old ranging
from 16 to 92 years old and most cases belonged to the
age group of 51–92 years. MRSA infections were signifi-
cantly decreased in the age group of ≤50 years old
(41.1% in 2011 vs 23.7% in 2012) (p = 0.011) while an
increase was seen in the age group of >50 years old
(54.7% in 2011 vs 75.4% in 2012) (p = 0.002). A total of
132 (63.2%) specimens were collected from male, 74
(35.4%) were from female and 3 specimens were un-
known. Age > 50 years old and male gender (p < 0.0001)
were the significant risk factors in the acquisition of
MRSA.
Fifty-nine percent (123 of 209) of MRSA strains were
HA-MRSA, 31% (65 of 209) were of CA-MRSA and the
remaining MRSA strains were not known. Some of the
MRSA strains had incomplete clinical data such as un-
known age, gender and MRSA types because the
patient’s medical records could not be retrieved from the
archived records. HA- and CA- MRSA infections were
significantly increased and decreased from year 2011 to
2012 (p = 0.001) respectively (Table 1).
Antimicrobial susceptibility testing
All the MRSA strains were sensitive to vancomycin with
the vancomycin MICs ranged from 0.38 – 2 μg/mL. One
hundred and six (50.7%) and 103 (49.3%) out of 209
strains had vancomycin MIC <1.5 μg/mL and ≥1.5 μg/mL,
respectively. A significant decreased was observed in the
number of strains with MIC <1.5 μg/mL (61.1% in 2011 vs
42.1% in 2012) and an increase was seen in the number of
strains with MIC ≥1.5 μg/mL (38.9% in 2011 vs 57.9% in
2012) (p = 0.008). Comparisons of patient demographics,
clinical features and the genotypes between the low
(<1.5 μg/mL) and high (≥ 1.5 μg/mL) vancomycin MIC
groups were shown in Table 2. There were no significant
differences in terms of age, gender and clinical diagnosis.
However, skin disease (p = 0.034) and SCCmec type
III (p = 0.0001) were found to be strongly associated
with elevated MIC (≥ 1.5 μg/mL), while SCCmec
type IV was associated with low vancomycin MIC
(p = 0.0001) (Table 2).
SCCmec types and the presence of PVL gene
For year 2011 MRSA strains, the predominant
SCCmec type was SCCmec type III (n = 61; 64.2%). A
total of 25 MRSA strains were SCCmec type IV and
further subtyped into SCCmec type IVa (n = 5; 5.3%)
and SCCmec type IVb (n = 5; 5.3%). Fifteen MRSA
strains could not be subtyped and were known as
Table 1 Comparisons between the patients’ demographics, phenotypic and genotypic characteristics of HA-MRSA and CA-MRSA in
2011 and 2012 (Continued)
SCCmec IVa 4 (9.8) 1 (4.2) 0.644 5 (7.7)
SCCmec IVb 2 (4.9) 0 (0) 0.527 2 (3.1)
Novel subtypes 7 (17.1) 10 (41.7) 0.042 17 (26.2)
SCCmec V 4 (9.8) 0 (0) 0.288 4 (6.2)
Untypeable 1 (2.4) 0 (0) 1.000 1 (1.5)
Not Known 10 (10.5) 11 (9.6) 21 (10)
SCCmec III 3 (30) 9 (81.8) 12 (57.1)
SCCmec IV
Novel subtypes 5 (50) 1 (9.1) 6 (28.6)
SCCmec V 2 (20) 0 (0) 2 (9.5)
Untypeable 0 (0) 1 (9.1) 1 (4.8)
PVL gene 5 (5.3) 0 (0) 0.018 5 (2.4)
Vancomycin MIC
< 1.5 μg/mL 58 (61.1) 48 (42.1) 0.008 106 (50.7)
≥ 1.5 μg/mL 37 (38.9) 66 (57.9) 103 (49.3)
CSF Cerebrospinal fluid
Fisher’s exact test done for categorical variables, p value < 0.05 was considered to be statistical significant and are indicated by bold text
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Table 2 Comparison between the vancomycin MICs with patient’s demographics, clinical diagnosis and genotypic characteristics of
MRSA in 2011 and 2012
Vancomycin MIC
< 1.5 μg/mL ≥ 1.5 μg/mL P value
2011 2012 Total 2011 2012 Total
N = 58 (%) N = 48 (%) N = 106 (%) N = 37 (%) N = 66 (%) N = 103 (%)
Age
≤ 50 years old 26 (44.8) 8 (16.7) 34 (32.1) 13 (35.1) 19 (28.8) 32 (31.1) 0.883
> 50 years old 29 (50) 40 (83.3) 69 (65.1) 23 (62.2) 46 (69.7) 69 (66.9) 0.884
Not Known 3 (5.2) 0 (0) 3 (2.8) 1 (2.7) 1 (1.5) 2 (1.9)
Gender
Female 18 (31) 22 (45.8) 40 (37.7) 12 (32.4) 22 (33.3) 34 (33) 0.563
Male 38 (65.5) 26 (54.2) 64 (60.4) 24 (64.9) 44 (66.7) 68 (66) 0.474
Not Known 2 (3.4) 0 (0) 2 (1.9) 1 (2.7) 0 (0) 1 (0.9)
Clinical diagnosis
Bacteraemia 25 (43.1) 24 (50) 49 (46.2) 15 (40.5) 27 (40.9) 42 (40.8) 0.486
Skin and soft tissue infections 26 (44.8) 20 (41.7) 46 (43.4) 20 (54.1) 31 46.9) 51 (49.5) 0.407
Osteomyelitis or septic arthritis 3 (5.2) 3 (6.3) 6 (5.7) 2 (5.4) 7 (10.6) 9 (8.7) 0.432
Meningitis 3 (5.2) 0 (0) 3 (2.8) 0 (0) 1 (1.5) 1 (0.9) 0.622
Pericarditis 1 (1.7) 1 (2.1) 2 (1.9) 0 (0) 0 (0) 0 (0) 0.498
Co-morbidities
Diabetes mellitus 12 (20.7) 27 (56.3) 39 (36.8) 12 (32.4) 25 (37.9) 37 (35.9) 1.000
Hypoglycaemia 1 (1.7) 0 (0) 1 (0.9) 0 (0) 0 (0) 0 (0) 1.000
Hypertension 12 (20.7) 24 (50) 36 (33.9) 11 (29.7) 23 (34.8) 34 (33) 1.000
Obesity 0 (0) 1 (2.1) 1 (0.9) 0 (0) 0 (0) 0 (0) 1.000
Chronic kidney disease and UTI 9 (15.5) 19 (39.6) 28 (26.4) 5 (13.5) 25 (37.9) 30 (29.1) 0.758
Cancer 8 (13.8) 6 (12.5) 14 (13.2) 3 (8.1) 2 (3) 5 (4.9) 0.052
Head injury 3 (5.2) 10 (20.8) 13 (12.3) 6 (16.2) 10 (15.2) 16 (15.5) 0.552
Liver disease 1 (1.7) 5 (10.4) 6 (5.7) 0 (0) 2 (3) 2 (1.9) 0.280
Respiratory disease 7 (12.1) 9 (18.8) 16 (15.1) 3 (8.1) 10 (15.2) 13 (12.6) 0.691
Cardiovascular disease 6 (10.3) 11 (22.9) 17 (16) 2 (5.4) 8 (12.1) 10 (9.7) 0.217
Gastrointestinal disease 2 (3.4) 3 (6.3) 5 (4.7) 0 (0) 2 (3) 2 (1.9) 0.446
Autoimmune disease 1 (1.7) 0 (0) 1 (0.9) 0 (0) 0 (0) 0 (0) 1.000
Bone and joint disorder 3 (5.2) 4 (8.3) 7 (6.6) 0 (0) 6 (9.1) 6 (5.8) 1.000
Endocrine disorder 0 (0) 2 (4.2) 2 (1.9) 0 (0) 1 (1.5) 1 (0.9) 1.000
Blood disorder 1 (1.7) 1 (2.1) 2 (1.9) 0 (0) 2 (3) 2 (1.9) 1.000
CMV 0 (0) 1 (2.1) 1 (0.9) 0 (0) 0 (0) 0 (0) 1.000
Skin disease 0 (0) 1 (2.1) 1 (0.9) 4 (10.8) 3 (4.5) 7 (6.8) 0.034
None 3 (5.2) 4 (8.3) 7 (6.6) 0 (0) 4 (6.1) 4 (3.9) 0.538
Not Known 24 (41.4) 2 (4.2) 26 (24.5) 12 (32.4) 8 (12.1) 20 (19.4) 0.407
SCCmec types
SCCmec II 0 (0) 0 (0) 0 (0) 2 (5.4) 0 (0) 2 (1.9) 0.242
SCCmec III 32 (55.2) 21 (43.8) 53 (50) 29 (78.4) 57 (86.4) 86 (83.5) 0.0001
SCCmec IV
SCCmec IVa 4 (6.9) 3 (6.3) 7 (6.6) 1 (2.7) 1 (1.5) 2 (1.9) 0.171
SCCmec IVb 5 (8.6) 0 (0) 5 (4.7) 0 (0) 0 (0) 0 (0) 0.060
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novel SCCmec type IV subtypes. There were two and
six strains typed as SCCmec type II and SCCmec type V,
respectively. For 2012 MRSA strains, three SCCmec types
were observed: SCCmec type III (n = 78; 68.4%), SCCmec
type IV (n = 34; 29.8%) and SCCmec type V (n = 1; 0.9%).
The SCCmec type IV strains were further subtyped as
SCCmec type IVa (n = 4; 3.5%) and novel type IV
SCCmec subtypes (n = 30; 26.3%). There were two
untypeable MRSA strains which harbour mecA gene
and no SCCmec type I was found in both years. PVL
gene was present in five MRSA strains from 2011 but
none was reported in 2012 MRSA strains. All PVL-positive
strains were CA-MRSA strains isolated from pus, tissue
and abscess and carried SCCmec type IV and V. There was
no significant difference in the number of strains carrying
SCCmec types II and III. However, a significant decreased
in the numbers of SCCmec types IVb (p = 0.018) and V
(p = 0.048) from 2011 to 2012 was observed.
Genotyping by PFGE
PFGE of SmaI-digested chromosomal DNA of 91 MRSA
strains generated 8 pulsotypes (A – H) each with 13 –
20 bands, with a Dice coefficient, F ranging from 0.5 to
1.0. Based on 80% similarity, three clusters (Cluster I to
Cluster III) and five singletons were observed. The ma-
jority of the strains (64.8%) were clustered in Cluster II,
followed by Cluster I which contained 20 strains (21.9%)
and Cluster III which contained 9 strain (6.6%). Pulso-
type C in Cluster II was the predominant pulsotype seen
with multiple subtypes (C1- C27) and followed by pulso-
type A in Cluster I with subtypes (A1-A12). Pulsotype E
in Cluster III was less common with fewer subtypes (E1-
E4) and pulsotypes B, D, F, G and H had no subtypes.
Most of the MRSA strains belonged to subtype C11,
which was the top major subtype and they were indistin-
guisable or clonally related. The presence of the clonally
or closely related MRSA strains despite being isolated
from different wards and different years may suggest the
persistence of this clone in this hospital and there was
transmission of this clone between wards (Fig. 1).
Determination of clonal relationships by MLST
MLST analysis revealed eight dfferent sequence types
(ST) which include ST239 (n = 61), ST22 (n = 19),
ST508 (n = 1), ST772 (n = 1), ST6 (n = 6), ST5 (n = 1),
ST1 (n = 1) and ST1137 (n = 1). ST6, ST22 and ST239
were observed in MRSA strains of both years, whereas
ST5, ST508 and ST772 were present among the 2011
MRSA strains and ST1 and ST1137 were found in 2012
MRSA strains. SCCmec type III belonged to ST239,
SCCmec type IV belonged to ST1, ST6, ST22 and
ST1137 while SCCmec type V belonged to ST5 and
ST772. Strains with untypeable SCCmec were repre-
sented by two STs (239 and 508). MRSA strains were
clustered into six clonal complexes (CC) based on the
similarity between STs in six of seven loci. ST239 was
assigned as the putative ancestral genotype of a sub-
group within CC8. ST1, ST5, ST6 and ST22 were identi-
fied as the ancestral genotypes of their corresponding
CCs. The newly discovered clones; ST508 and ST1137
were observed in this study and they belonged to CC45
and CC22, respectively (Fig. 2) (Table 3).
Discussion
MRSA is known to be one of the most prominent patho-
gens that causes HA and CA- associated infections in
Malaysian hospitals. In this study, 59% (123 of 209) of
MRSA strains were HA-MRSA and 31% (65 of 209)
were of CA-MRSA. Most of the HA-MRSA infections
were caused by SCCmec type III (n = 91; 73.9%) strains.
Although SCCmec IV and V have been reported to occur
in the community [9], most patients seem to acquire
these strains in this hospital based on the proportions of
SCCmec IV (n = 29; 23.6%) and V (n = 1; 0.8%), indicat-
ing the invasion of these strains into hospitals and may
replace the classical HA-MRSA strains due to their
unique characteristics and faster growth patterns [27].
CA-MRSA infections in this hospital have decreased
from 41 to 24 cases in 2011 and 2012, respectively. The
high prevalence of SCCmec type III (n = 36; 55.4%)
among the CA-MRSA strains might indicate that this
MRSA hospital strain has spread to the community. As
Table 2 Comparison between the vancomycin MICs with patient’s demographics, clinical diagnosis and genotypic characteristics of
MRSA in 2011 and 2012 (Continued)
Novel subtypes 13 (22.4) 23 (47.9) 36 (33.9) 2 (5.4) 7 (10.6) 9 (8.7) 0.0001
SCCmec V 3 (5.2) 1 (2.1) 4 (3.8) 3 (8.1) 0 (0) 3 (2.9) 1.000
Untypeable 1 (1.7) 0 (0) 1 (0.9) 0 (0) 1 (1.5) 1 (0.9) 1.000
UTI = Urinary Tract Infection, CMV = Cytomegalovirus
Head injury includes: basal ganglia bleed, subdural hematoma and stroke. Liver disease includes: alcoholic liver disease, liver cirrhosis. Respiratory disease includes:
pneumonia, pulmonary embolism, chronic obstructive pulmonary disease, acute respiratory distress syndrome. Cardiovascular disease includes: mitral valve
regurgitation, ischaemic heart disease, acute coronary syndrome, congestive cardiac failure. Gastrointestinal disease includes: acute gastroenteritis, Crohn’s disease,
perforated diverticular disease, intestinal obstruction. Autoimmune disease includes: Systemic lupus erythematosus. Endocrine disorder includes: thyroid disease,
primary hypothyroidism. Blood disorder includes: myelofibrosis, anaemia. Skin disease includes: Stevens Johnson Syndrome, Bullous pemphigoid, exfoliative
dermatitis and pemphigus vulgaris
Fisher’s exact test done for categorical variables, p value < 0.05 was considered to be statistical significant and are indicated by bold text
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Fig. 1 Dendrogram of MRSA PFGE patterns generated by UPGMA clustering method using Dice coefficient. The dotted line indicates an
arbitrary 80% similarity demarcation
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stated by Chen et al. [28] in a recent study in China,
SCCmec III-ST239 is beginning to appear in CA-MRSA
isolates. In addition, in the first international surveillance
study on the CA-MRSA epidemiology in Asian coun-
tries, have revealed the spreading of HA-MRSA isolates
to the community, given the presence of SCCmec types
I, II and III in CA-MRSA isolates from Taiwan, Korea,
Hong Kong, Philippines, Thailand and Vietnam [29].
Based on the distributions analysis in Table 1, MRSA
infections were significantly correlated with male pa-
tients and between the ages of 51 and 92 years.
The existence of the vancomycin creep phenomenon
was demonstrated by the increased percentages of
MRSA strains with MIC ≥1.5 μg/mL over a 2-year
period. In addition, skin disease and SCCmec type III
were found to be significantly associated with high
vancomycin MIC. This is possibly due to the previous
exposure of MRSA strains to vancomycin which led to
the changes in the characteristics of bacteria such as
bacterial cell wall alterations, preventing vancomycin to
reach its target site [30].
SCCmec type III was the predominant SCCmec type
for year 2011 (n = 61; 64.2%) and 2012 (n = 78; 68.4%)
which is consistent with previous reports in Malaysian
hospitals done by Lim et al. [11] and Ghaznavi-Rad et al.
[13]. SCCmec type III was also common in Asian coun-
tries such as Taiwan, Singapore, Thailand and Indonesia
[19]. For year 2011 MRSA strains, 25 MRSA strains are
SCCmec type IV and were further subtyped as SCCmec
type IVa and IVb. Fifteen SCCmec type IV MRSA strains
could not be further subtyped and might be the novel
type IV SCCmec subtypes. SCCmec types II and V were
also observed. For 2012 MRSA strains, other than
SCCmec type III, SCCmec type IV and V were also
Fig. 2 Population snapshot of MRSA strains from blood source in the MLST database. Individual sequence type (ST) is highlighted in black (STs in
the database), green (STs in this study) and pink (STs in both the database and in this study) and is represented by each circle. The size of the
circle indicates the frequency of a particular ST and the colour of the circle represents founders or subgroup founders. Blue circles are ‘founders’
[defined as ST with many single locus variants (SLVs) and is prevalent within a CC], whereas yellow circle are ‘subgroup founders’. The most
prevalent ST in this study was ST239, which is the subgroup founder within CC8
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Table 3 Comparison between SCCmec types with the patient’s demographic, clinical diagnosis and molecular characteristics of
MRSA strains isolated from blood
SCCmec III SCCmec IV SCCmec V Untypeable Total
N = 60 (%) N = 27 (%) N = 2 (%) N = 2 (%) N = 91 (%)
Age
≤ 50 years old 12 (20) 3 (11.1) 0 (0) 0 (0) 15 (16.5)
> 50 years old 47 (78.3) 23 (85.2) 2 (100) 2 (100) 74 (81.3)
Not Known 1 (1.7) 1 (3.7) 0 (0) 0 (0) 2 (2.2)
Gender
Female 30 (50) 10 (37) 0 (0) 0 (0) 40 (43.9)
Male 29 (48.3) 16 (59.3) 2 (100) 2 (100) 49 (53.8)
Not Known 1 (1.7) 1 (3.7) 0 (0) 0 (0) 2 (2.2)
Co-morbidities
Diabetes mellitus 20 (33.3) 11 (40.7) 1 (50) 0 (0) 32 (35.2)
Hypertension 22 (36.7) 12 (44.4) 1 (50) 0 (0) 35 (38.5)
Obesity 0 (0) 1 (3.7) 0 (0) 0 (0) 1 (1.1)
Chronic kidney disease and UTI 24 (40) 14 (51.9) 0 (0) 0 (0) 38 (41.8)
Cancer 8 (13.3) 2 (7.4) 0 (0) 0 (0) 10 (10.9)
Head injury 11 (18.3) 4 (14.8) 0 (0) 1 (50) 16 (17.6)
Liver disease 4 (6.7) 2 (7.4) 0 (0) 0 (0) 6 (6.6)
Respiratory disease 12 (20) 3 (11.1) 1 (50) 0 (0) 16 (17.6)
Cardiovascular disease 4 (6.7) 8 (29.6) 2 (100) 0 (0) 14 (15.4)
Gastrointestinal disease 4 (6.7) 1 (3.7) 0 (0) 0 (0) 5 (5.5)
Autoimmune disease 1 (1.7) 0 (0) 0 (0) 0 (0) 1 (1.1)
Bone and joint disorder 1 (1.7) 2 (7.4) 0 (0) 0 (0) 3 (3.3)
Endocrine disorder 0 (0) 2 (7.4) 0 (0) 0 (0) 2 (2.2)
Blood disorder 2 (3.3) 0 (0) 0 (0) 0 (0) 2 (2.2)
CMV 1 (1.7) 0 (0) 0 (0) 0 (0) 1 (1.1)
Skin disease 7 (11.7) 0 (0) 0 (0) 0 (0) 7 (7.7)
None 1 (1.7) 0 (0) 0 (0) 0 (0) 1 (1.1)
Not known 7 (11.7) 5 (18.5) 0 (0) 1 (50) 13 (14.3)
No of comorbidities
0 8 (13.3) 5 (18.5) 0 (0) 1 (50) 14 (15.4)
1 19 (31.7) 5 (18.5) 1 (50) 1 (50) 26 (28.6)
2 11 (18.3) 6 (22.2) 0 (0) 0 (0) 17 (18.7)
3 12 (20) 1 (3.7) 0 (0) 0 (0) 13 (14.3)
≥ 4 10 (16.7) 10 (37) 1 (50) 0 (0) 21 (23.1)
Source of bacteraemia
Primary bacteraemia 38 (63.3) 19 (70.4) 2 (100) 2 (100) 61 (67)
Catheter-related 7 (11.7) 5 (18.5) 0 (0) 0 (0) 12 (13.2)
Skin and soft tissue infection 6 (10) 0 (0) 0 (0) 0 (0) 6 (6.6)
Surgical site infection 1 (1.7) 0 (0) 0 (0) 0 (0) 1 (1.1)
Pneumonia 5 (8.3) 2 (7.4) 0 (0) 0 (0) 7 (7.7)
Implant-related infection 0 (0) 1 (3.7) 0 (0) 0 (0) 1 (1.1)
More than one source 3 (5) 0 (0) 0 (0) 0 (0) 3 (3.3)
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observed. The SCCmec type IV strains are further sub-
typed as SCCmec type IVa and novel type IV SCCmec
subtypes. There were untypeable MRSA strains which
harbours mecA gene detected in each year. These strains
may indicate new or variant SCCmec types which should
be further analysed [31]. The prevalence of PVL gene
among 2011 MRSA strains was 5.3% and most of them
caused skin and soft tissue infections. No PVL gene was
detected in year 2012 strains.
MRSA bacteraemia is common in hospitals worldwide,
including Malaysia and is associated with high mortality
rate and vancomycin treatment failure. Therefore, se-
lected MRSA strains from blood were further typed by
MLST and PFGE in order to determine the molecular
characteristics of MRSA bacteraemia in both years. In
this study, the MRSA yield from blood for both years
were accounted for 43.5% (n = 91) with 81.3% (n = 74) re-
corded in patients aged 51 years and more. Most of the
bacteraemia cases were primary bacteraemia (n = 61; 67%).
Diabetes (n = 32; 35.2%), hypertension (n = 35; 38.5%) and
chronic kidney disease (n = 38; 41.8%) were the most
common underlying comorbidities. MRSA bacteraemia
were seen to be caused by HA-MRSA strains type III
(n = 36) and IV (n = 15) and CA-MRSA strains type III
(n = 15), IV (n = 9) and V (n = 2) as shown in Table 3.
Analysis of the PFGE patterns have supported the possibil-
ity of the spread of SCCmec type III-ST239 into the com-
munity as they are closely related to the HA-MRSA clone
of SCCmec type III-ST239. Whereas, SCCmec type IV
strains were seen to have invaded and resided in this hos-
pital as nosocomial MRSA strains. Due to their multiplica-
tion and transmission rates, there is a possibility for these
type IV strains to replace and become the predominant
endemic MRSA clone in this hospital [32].
Based on the PFGE dendrogram, 20 MRSA strains
within Cluster I were closely related as they shared more
than 80% similarity. Although they were from different
years, they shared the same characteristics of having
SCCmec type IV and ST22. MRSA strain of SCCmec
type IV-ST1137 was also assigned in this cluster because
Table 3 Comparison between SCCmec types with the patient’s demographic, clinical diagnosis and molecular characteristics of
MRSA strains isolated from blood (Continued)
Type of MRSA
HA-MRSA 36 (60) 15 (55.6) 0 (0) 0 (0) 51 (56)
CA-MRSA 15 (25) 9 (33.3) 2 (100) 1 (50) 27 (29.7)
Not Known 9 (15) 3 (11.1) 0 (0) 1 (50) 13 (14.3)
CC/ST
CC1
ST1 0 (0) 1 (3.7) 0 (0) 0 (0) 1 (1.1)
ST772 0 (0) 0 (0) 1 (50) 0 (0) 1 (1.1)
CC5
ST5 0 (0) 0 (0) 1 (50) 0 (0) 1 (1.1)
CC6
ST6 0 (0) 6 (22.2) 0 (0) 0 (0) 6 (6.6)
CC8
ST239 60 (100) 0 (0) 0 (0) 1 (50) 61 (67)
CC22
ST22 0 (0) 19 (70.4) 0 (0) 0 (0) 19 (20.9)
ST1137 0 (0) 1 (3.7) 0 (0) 0 (0) 1 (1.1)
CC45
ST508 0 (0) 0 (0) 0 (0) 1 (50) 1 (1.1)
Vancomycin MIC
< 1.5 μg/mL 22 (36.7) 25 (92.6) 1 (50) 1 (50) 49 (53.8)
≥ 1.5 μg/mL 38 (63.3) 2 (7.4) 1 (50) 1 (50) 42 (46.2)
UTI = Urinary Tract Infection, CMV = Cytomegalovirus
Head injury includes: basal ganglia bleed, subdural hematoma and stroke. Liver disease includes: alcoholic liver disease, liver cirrhosis. Respiratory disease includes:
pneumonia, pulmonary embolism, chronic obstructive pulmonary disease, acute respiratory distress syndrome. Cardiovascular disease includes: mitral valve
regurgitation, ischaemic heart disease, acute coronary syndrome, congestive cardiac failure. Gastrointestinal disease includes: acute gastroenteritis, Crohn’s disease,
perforated diverticular disease, intestinal obstruction. Autoimmune disease includes: Systemic lupus erythematosus. Endocrine disorder includes: thyroid disease,
primary hypothyroidism. Blood disorder includes: myelofibrosis, anaemia. Skin disease includes: Stevens Johnson Syndrome, Bullous pemphigoid, exfoliative
dermatitis and pemphigus vulgaris
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ST1137 was shown to belong in the same CC as ST22.
Another six SCCmec type IV MRSA strains were
assigned in Cluster III as they shared similar characteristic
of having MLST ST6. Most novel SCCmec type IV strains
(n = 18) were assigned in the same Cluster I as SCCmec
type IVb. SCCmec type IVa displayed no epidemiological
linkage with SCCmec type IVb. There was a substantial
genetic diversity in SCCmec type IV by the presence of
various sequence types (ST1, ST5, ST6, ST22 and
ST1137) indicating its capability to transfer between
different genetic clones of S. aureus. All the MRSA strains
that possessed SCCmec type III-ST239 were distributed in
Cluster II.
The two SCCmec type V strains found in this study
were CA-MRSA, PVL negative, had low vancomycin
MIC and assigned as singleton due to difference in STs;
ST772 and ST5. Previous studies done in the same
hospital by Lim et al. [11] and Sam et al. [33] had
reported the presence of ST22 and ST6 in SCCmec type
IV and ST772 in SCCmec V. However, no local study
has reported the presence of ST1 and S1137 in SCCmec
type IV strains and ST5 in SCCmec type V strain. Inter-
esting findings were that ST1-SCCmec IV has been
reported by Otter and French in a study done on drug
users and the homeless in South London [34] and
ST5-SCCmec V was found in Japanese CA-MRSA iso-
lates [35] which may indicate the invasion of these
clones into Malaysia. The occurrence of the inter-
national major clones ST239-SCCmec III and ST22-
SCCmec IV in Malaysia as well in other countries
exhibited the epidemic nature of these clones [13].
To date, there is no study reporting ST1137-SCCmec
type IV strains.
The untypeable SCCmec strains with ST239 and
ST508 were not assigned to any clusters and appeared
as singleton by PFGE. The untypeable CA-MRSA
strain with novel ST508 might have derived from
ST45 as it appeared to be a single locus (SLV) variant
of ST45. According to Berglund et al. [36], MRSA
strains that could not be typed by SCCmec typing
might cause by some genetic rearrangement or muta-
tions. This led to the emergence of a new highly
pathogenic CA-MRSA clone which could have spread
to the hospital. ST45 was previously reported as an
epidemic strains in Germany and the Netherlands
[37] and was present in MRSA bacteraemia isolates in
a study done in Switzerland [38].
PFGE was shown to be more discriminatory than
MLST in subtyping the MRSA strains. Based on PFGE,
the strains had greater diversity with Simpson’s index of
diversity, D of 0.946 (C.I.N.A. 0.916-0.976), on the other
hand, for MLST, the strains were less diverse with Simp-
son’s index of diversity, D of 0.508 (C.I.N.A. 0.403-
0.613). The majority of MRSA strains in this 2-year
study period belonged to the pandemic clone SCCmec
III-ST239 and most of them had pulsotype C. The
predominance of this pulsotype could be due to the
increase in nosocomial transmission within this hos-
pital. In addition, the presence of this clone indicates
the persistence of this clone and was identified as an
endemic strain in this hospital [39].
Limitations
The limitations for this study is the clinical data for
some 2011 and 2012 MRSA strains could not be
retrieved, and hence a comprehensive correlation be-
tween phenotypic, molecular and clinical data cannot
be made.
Conclusions
MRSA strains belonging to SCCmec type III were pre-
dominant in this hospital over the 2-year study period
and the prevalence of PVL gene among 2011 MRSA
strains were 5.3% with none detected in 2012 MRSA
strains. The characteristics of MRSA strains that caused
bacteraemia were genetically diverse by the presence of
different clones circulating in this hospital, in which the
majority belonged to SCCmec type III with MLST
ST239 and exhibited pulsotype C. However, the presence
of SCCmec type IV with MLST ST22 which is usually
community-acquired is gaining prominence as they have
become nosocomial pathogens and may replace the pre-
dominant SCCmec type III strains in this hospital. There
were also emergence of novel clones which require fur-
ther studies and proper monitoring as these clones may
have epidemic and pathogenic potentials that could pose
serious threat to public health.
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